Key result
In vivo gene transfer shows potential for treating common arrhythmias, including rate control in atrial fibrillation and pacemaking activity, though the field remains in its infancy.
Gene transfer techniques offer a promising but early-stage approach for the treatment of cardiac arrhythmias, requiring further solutions before human application.
Gene therapy for arrhythmias remains experimental; leaves open critical delivery, durability, and safety questions before human trials.
Therapy for cardiac arrhythmias is inadequate, based on current options. Gene therapy has shown tremendous potential to investigate pathophysiology and potential therapies for cardiac diseases. The current work reviews the possibilities for application of in vivo gene transfer to treatment of common arrhythmias, including vector selection, delivery technique, and data on in vivo gene transfer for rate control in atrial fibrillation and for pacemaking activity. Arrhythmia gene therapy is a field in its infancy, and future human applications are dependent on solutions to the problems discussed in this review.
No takes yet. Share an insight, caveat, or question.
Donahue et al. (2004) conducted a review in Cardiac arrhythmias. In vivo gene transfer was evaluated. In vivo gene transfer shows potential for treating common arrhythmias, including rate control in atrial fibrillation and pacemaking activity, though the field remains in its infancy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: